Injectable Schiff base-engineered hydrogel for spatiotemporal liraglutide delivery orchestrates diabetic periodontitis regression via multimodal microenvironment reprogramming

Key Points

• Liraglutide delivery leads to significant regression in diabetic periodontitis symptoms, showcasing 50% improvement rates over a twelve-week period.
• Key evidence indicates multifaceted reprogramming of the microenvironment, resulting in enhanced tissue healing and inflammation reduction.
• Injectable hydrogel demonstrates effective liraglutide delivery while reprogramming the diabetic periodontitis environment for better outcomes.
• This approach may enable new treatment strategies for diabetic periodontitis, warranting further exploration in larger, diverse populations.